Regeneron's pricing deal with federal government may have 'far-reaching consequences,' analysts say
Regeneron Pharmaceuticals Inc.’s agreement with the federal government to limit the list price of any new COVID monoclonal antibody commercialized as a...
Source: marketwatch.com